{"id":17553,"date":"2020-05-30T11:43:00","date_gmt":"2020-05-30T11:43:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2574988"},"modified":"2020-05-30T11:43:00","modified_gmt":"2020-05-30T11:43:00","slug":"bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/","title":{"rendered":"Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip\u00f4le SA"},"content":{"rendered":"<p align=\"justify\"><strong>BONE THERAPEUTICS<\/strong>&nbsp;the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces that it has received a transparency notification dated 26&nbsp;May 2020 indicating that the shareholdings held by S.R.I.W. SA (Soci&eacute;t&eacute; R&eacute;gionale d&rsquo;Investissement de Wallonie) and its subsidiary Sofip&ocirc;le SA (Soci&eacute;t&eacute; Wallonne pour le Financement des Infrastructures des P&ocirc;les de Comp&eacute;titivit&eacute;) have crossed above the threshold of 10% following the issuance of new shares of Bone Therapeutics via a private placement on 28&nbsp;April 2020. The new shares were delivered to the participating investors on 30&nbsp;April 2020.<\/p>\n<p align=\"justify\">The notification dated 26&nbsp;May 2020 contains the following information:<\/p>\n<ul type=\"disc\">\n<li>Reason for the notification:&nbsp;<em>Acquisition or disposal of voting securities or voting rights<\/em><\/li>\n<li>Notification by:&nbsp;<em>A parent undertaking or a controlling person<\/em><\/li>\n<li>Persons subject to the notification requirement:&nbsp;<em>S.R.I.W. SA &amp; Sofip&ocirc;le SA<\/em><\/li>\n<li>Transaction date:&nbsp;<em>28 April 2020<\/em><\/li>\n<li>Threshold that is crossed:&nbsp;<em>10%<\/em><\/li>\n<li>Denominator:&nbsp;<em>11,505,043<\/em><\/li>\n<li>Notified details:<\/li>\n<\/ul>\n<table class=\"gnw_table_border_collapse hugin\">\n<tbody>\n<tr>\n<td class=\"gnw_border_top_solid gnw_border_right_solid gnw_border_bottom_solid gnw_border_left_solid gnw_align_center hugin\"><strong>Voting rights<\/strong><\/td>\n<td class=\"gnw_border_top_solid gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\"><strong>Previous notification<\/strong><\/td>\n<td class=\"gnw_border_top_solid gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\" colspan=\"2\"><strong>After the transaction<\/strong><\/td>\n<\/tr>\n<tr>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_border_left_solid gnw_align_center hugin\"><strong>Holders of voting rights<\/strong><\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\"><strong># of voting rights<\/strong><\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\"><strong># of voting rights<\/strong><\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\"><strong>% of voting rights<\/strong><\/td>\n<\/tr>\n<tr>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_border_left_solid gnw_align_center hugin\">S.R.I.W. SA<\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\">344,530<\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\">344,530<\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\">2.99%<\/td>\n<\/tr>\n<tr>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_border_left_solid gnw_align_center hugin\">Sofip&ocirc;le SA<\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\">703,823<\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\">903,139<\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\">7.85%<\/td>\n<\/tr>\n<tr>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_border_left_solid gnw_align_center hugin\"><strong>Total voting rights held by S.R.I.W and Sofip&ocirc;le<\/strong><\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\"><strong>1,048,353<\/strong><\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\"><strong>1,247,669<\/strong><\/td>\n<td class=\"gnw_border_right_solid gnw_border_bottom_solid gnw_align_center hugin\"><strong>10.84%<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p align=\"justify\">&middot;Full chain of controlled undertakings through which the holding is effectively held:&nbsp;<em>The Walloon Region holds 99.43% of S.R.I.W. SA which controls 60% of the shares of Sofip&ocirc;le SA.<\/em><\/p>\n<p align=\"justify\">The notification can be consulted on the website of Bone Therapeutics, under the heading &ldquo;<em>Shareholder Information<\/em>&rdquo;.<\/p>\n<p align=\"justify\"><strong><em>&nbsp;<\/em><\/strong><\/p>\n<p align=\"justify\"><strong><em>About Bone Therapeutics<\/em><\/strong><\/p>\n<p align=\"justify\"><em>Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation.<\/em><\/p>\n<p align=\"justify\"><em>Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is currently in phase&nbsp;III development for the treatment of pain in knee osteoarthritis. Consisting of a unique mix of plasma proteins, hyaluronic acid &#8211; a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.<\/em><\/p>\n<p align=\"justify\"><em>Bone Therapeutics&rsquo; other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via a proprietary, scalable cutting-edge manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase&nbsp;IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process.<\/em><\/p>\n<p align=\"justify\"><em>The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy, maxillofacial and dental applications.<\/em><\/p>\n<p align=\"justify\"><em>Bone Therapeutics&rsquo; cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at www.bonetherapeutics.com.<\/em><\/p>\n<p align=\"justify\"><strong><em>&nbsp;<\/em><\/strong><\/p>\n<p align=\"justify\"><strong><em>For further information, please contact:<\/em><\/strong><\/p>\n<p align=\"justify\"><strong><em>Bone Therapeutics SA<\/em><\/strong><br \/>Miguel Forte, MD, PhD, Chief Executive Officer<br \/>Jean-Luc Vandebroek, Chief Financial Officer<br \/>Tel: +32 (0) 71 12 10 00<br \/>investorrelations@bonetherapeutics.com<\/p>\n<p align=\"justify\">International Media Enquiries:<br \/><strong><em>Image Box Communications<\/em><\/strong><br \/>Neil Hunter \/ Michelle Boxall<br \/>Tel: +44 (0)20 8943 4685<br \/>neil@ibcomms.agency \/ michelle@ibcomms.agency<\/p>\n<p align=\"justify\">For French Media and Investor Enquiries:<br \/><strong><em>NewCap Investor Relations &amp; Financial Communications<\/em><\/strong><br \/>Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouill&eacute;<br \/>Tel: +33 (0)1 44 71 94 94<br \/>bone@newcap.eu<\/p>\n<p class=\"tags\">\n<div><strong>See Campaign: <\/strong><a href=\"http:\/\/bonetherapeutics.com\" target=\"_blank\">http:\/\/bonetherapeutics.com<\/a><br \/><b>Contact Information:<\/b><br \/>Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouill<br \/>\nTel: +33 (0)1 44 71 94 94<br \/>\nbone@newcap.eu<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"\"><\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/wire\/\" rel=\"category tag\">Wire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/disclosure-newswire\/\" rel=\"category tag\">Disclosure Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/global-regions\/united-states\/\" rel=\"category tag\">United States<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" alt=\"image\" width=\"400\" height=\"300\" class=\"cwdfimg\" \/><\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouill\u00e9<br \/>\nTel: +33 (0)1 44 71 94 94<br \/>\nbone@newcap.eu<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BONE THERAPEUTICS&nbsp;the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces that it has received a transparency notification dated 26&nbsp;May 2020 indicating that the shareholdings held by S.R.I.W. SA (Soci&eacute;t&eacute; R&eacute;gionale d&rsquo;Investissement de Wallonie) and its subsidiary Sofip&ocirc;le &hellip; <a href=\"https:\/\/icrowdnewswire.com\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/\">Continue reading <span>Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip&ocirc;le SA<\/span><\/a> <a href=\"https:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":46,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[56,3,22,54],"tags":[],"class_list":["post-17553","post","type-post","status-publish","format-standard","hentry","category-disclosure-newswire","category-english","category-united-states","category-wire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip\u00f4le SA - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip\u00f4le SA - Business\" \/>\n<meta property=\"og:description\" content=\"BONE THERAPEUTICS&nbsp;the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces that it has received a transparency notification dated 26&nbsp;May 2020 indicating that the shareholdings held by S.R.I.W. SA (Soci&eacute;t&eacute; R&eacute;gionale d&rsquo;Investissement de Wallonie) and its subsidiary Sofip&ocirc;le &hellip; Continue reading Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip&ocirc;le SA Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-30T11:43:00+00:00\" \/>\n<meta name=\"author\" content=\"Asiya\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Asiya\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/\",\"url\":\"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/\",\"name\":\"Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip\u00f4le SA - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"datePublished\":\"2020-05-30T11:43:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/3a37b5ed16b9ebaf70290330c45a2e37\"},\"breadcrumb\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip\u00f4le SA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/3a37b5ed16b9ebaf70290330c45a2e37\",\"name\":\"Asiya\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d4d7dcc41e3f5a5cad4cf78eca935d2f4c65cc9a91e376789d357e29806bcb91?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d4d7dcc41e3f5a5cad4cf78eca935d2f4c65cc9a91e376789d357e29806bcb91?s=96&d=mm&r=g\",\"caption\":\"Asiya\"},\"sameAs\":[\"https:\/\/icrowdnewswire.com\/fc\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/asiya\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip\u00f4le SA - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/","og_locale":"en_US","og_type":"article","og_title":"Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip\u00f4le SA - Business","og_description":"BONE THERAPEUTICS&nbsp;the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces that it has received a transparency notification dated 26&nbsp;May 2020 indicating that the shareholdings held by S.R.I.W. SA (Soci&eacute;t&eacute; R&eacute;gionale d&rsquo;Investissement de Wallonie) and its subsidiary Sofip&ocirc;le &hellip; Continue reading Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip&ocirc;le SA Continue Reading &rarr;","og_url":"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/","og_site_name":"Business","article_published_time":"2020-05-30T11:43:00+00:00","author":"Asiya","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Asiya","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/","url":"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/","name":"Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip\u00f4le SA - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"datePublished":"2020-05-30T11:43:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/3a37b5ed16b9ebaf70290330c45a2e37"},"breadcrumb":{"@id":"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/ipsnews.net\/business\/2020\/05\/30\/bone-therapeutics-sa-transparency-notification-received-from-s-r-i-w-sa-and-sofipole-sa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofip\u00f4le SA"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/3a37b5ed16b9ebaf70290330c45a2e37","name":"Asiya","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d4d7dcc41e3f5a5cad4cf78eca935d2f4c65cc9a91e376789d357e29806bcb91?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d4d7dcc41e3f5a5cad4cf78eca935d2f4c65cc9a91e376789d357e29806bcb91?s=96&d=mm&r=g","caption":"Asiya"},"sameAs":["https:\/\/icrowdnewswire.com\/fc"],"url":"https:\/\/ipsnews.net\/business\/author\/asiya\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/17553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/46"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=17553"}],"version-history":[{"count":0,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/17553\/revisions"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=17553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=17553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=17553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}